Adam D Cohen MD

Hematologic Oncology

Associate Professor, Medicine, Perelman School of Medicine, University of Pennsylvania. Director, Myeloma Immunotherapy, and Co-Director, Amyloidosis Program, Abramson Cancer Center, University of Pennsylvania

Join to view full profile

3400 Civic Center Blvd# 2Philadelphia, PA 19104
Phone+1 215-615-5858

Dr. Cohen is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cohen's full profile Already have an account?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
University of Pennsylvania Health SystemResidency, Internal Medicine, 1999 - 2002
Perelman School of Medicine at the University of PennsylvaniaClass of 1999

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

PA State Medical License 2000 - 2026
NY State Medical License 2001 - 2008
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017

Clinical Trials

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
ACTIVE_NOT_RECRUITING
PHASE3
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
COMPLETED
PHASE1
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
TERMINATED
PHASE1, PHASE2

Publications & Presentations

PubMed

CART-immune-related adverse events after BCMA CAR-T therapy.
Luca Paruzzo, Matthew Ho, Julia Han Noll, Alfred L Garfall, Adam D Cohen
Molecular Therapy. Oncology. 2026-09-17
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
Adam D Cohen, Joshua Richter, Suzanne Trudel, Alexander Lesokhin, Jacob P Laubach
Nature Medicine. 2026-08-01
Neuralgic Amyotrophy Following B-Cell Maturation Antigen-Directed CAR-T Therapy.
Eduardo J Pérez-Torres, Daria V Madeeva, Adam D Cohen, Alfred L Garfall, Chafic Karam
Muscle & Nerve. 2026-07-30

Abstracts/Posters

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma
Adam D. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to El...
Adam D. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
Adam D. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Immunotherapy in Myeloma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

$Relapsed or Refractory Multiple Myeloma: Early-Phase Trial Investigates Novel Bispecific Antibody$
Relapsed or Refractory Multiple Myeloma: Early-Phase Trial Investigates Novel Bispecific AntibodyJuly 27th, 2026
Penn Medicine at the 2025 ASH Annual MeetingDecember 2nd, 2025
Multiple Myeloma Treatment: A Roadmap for Long-Term CareNovember 11th, 2025